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Abstract The association of HFE (High Iron FE) major var-
iants with breast cancer risk and behavior has been a matter of
discussion for a long time. However, their impact on the ex-
pression of iron-related proteins in the breast cancer tissue has
never been addressed. In the present study, hepcidin,
ferroportin 1, transferrin receptor 1 (TfR1), and ferritin expres-
sions, as well as tissue iron deposition were evaluated in a
collection of samples from breast cancers patients and ana-
lyzed according to the patients’ HFE genotype. Within the
group of patients with invasive carcinoma, those carrying
the p.Cys282Tyr variant in heterozygosity presented a higher
expression of hepcidin in lymphocytes and macrophages than
wild-type or p.His63Asp carriers. An increased expression of
TfR1 was also observed in all the cell types analyzed but only
in p.Cys282Tyr/p.His63Asp compound heterozygous pa-
tients. A differential impact of the two HFE variants was fur-
ther noticed with the observation of a significantly higher
percentage of p.Cys282Tyr heterozygous patients presenting
tissue iron deposition in comparison to p.His63Asp heterozy-
gous. In the present cohort, no significant associations were
found between HFE variants and classical clinicopathological
markers of breast cancer behavior and prognosis. Although
limited by a low sampling size, our results provide a new
possible explanation for the previously reported impact of
HFE major variants on breast cancer progression, i.e., not by
influencing systemic iron homeostasis but rather by differen-
tially modulating the local cellular expression of iron-related
proteins and tissue iron deposition.
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Introduction
Iron is an essential trace element for the human body, as a
critical component of several signaling, transporter and stor-
age molecules involved in energy production and intermediate
metabolism [1, 2]. However, its characteristic chemistry con-
tributes to the formation of hazardous molecules, such as hy-
droxyl radicals and hydrogen peroxide, when in excess [3, 4].
Although most organisms have their proper mechanisms to
regulate iron homeostasis and avoid free iron toxicity, current
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knowledge suggests that the deregulation of these mecha-
nisms may contribute to a number of chronic diseases [5].
Iron is thought to promote carcinogenesis through iron-
induced oxidative stress, modulation of signaling networks
associated with malignancy and by providing selective advan-
tage to rapidly growing tumor cells [6, 7].
HFE (High Iron Fe) is a MHC class-I like protein that acts
as a gatekeeper of systemic iron homeostasis by controlling
hepatic hepcidin levels [8, 9]. Hepcidin, in turn, maintains
normal plasma iron levels by regulating iron release from cells
through the binding to its receptor, the iron exporter
ferroportin 1 [10, 11]. A proposed molecular mechanism
places HFE and Transferrin Receptor 1 (TfR1) in an iron-
sensing complex which is disrupted by binding of circulating
holotransferrin with a higher affinity for TfR1 [12]. Upon
TfR1 dissociation,HFE is able to relocate to TfR2 and interact
with the bone morphogenetic protein (Bmp) co-receptor
Hemojuvelin [12, 13], involved in signal communication up-
on binding of the Bmp ligands, and whose interaction leads to
the activation of hepcidin transcription [14–16]. However,
previous evidences from others suggest that HFE may also
act as a regulator of iron uptake through its direct interaction
with the TfR1 [17–19]. HFE gene variants p.Cys282Tyr and
p.His63Asp are very common in European derived popula-
tions. The p.Cys282Tyr variant disrupts the association of
HFE with β-2 microglobulin, reducing the cellular surface
expression of HFE [19–21]. This alteration is responsible for
the large majority of hereditary hemochromatosis cases [19].
The p.His63Asp variant is believed to lower the HFE protein
affinity for TfR1 [22], but its association with iron overload is
controversial [23–25]. Although epidemiological studies have
been inconsistent in supporting an association between
HFE major variants and an increased risk for breast
cancer [7], it is plausible to assume that, by interfering
with the cellular and tissue iron homeostasis, they may
affect the cancer cell phenotype.
We have previously shown that the deregulation of iron-
related proteins in breast cancer, more specifically hepcidin,
ferroportin 1 (FPN1), TfR1 and ferritin (FT), is not restricted
to epithelial cells, but also extends to cells of the tumor mi-
croenvironment [26]. To our knowledge, no other group has
attempted to verify if theHFEmajor variants had an impact on
the expression of iron-related proteins in the neoplastic
context.
Materials and Methods
Sample Characterization
A previously characterized group of human breast tissue sam-
ples, archived at the Pathology Service at Centro Hospitalar
do Porto, was used in this study. This cohort consisted of 119
samples, including 56 cases of invasive ductal carcinomas
(IDC), 14 cases of ductal carcinomas in situ (DCIS) and 49
samples without evidence of breast disease obtained from
breast reduction aesthetic surgery. The study has been previ-
ously approved by the local Research Ethics Committees, as
part of a more extended study (see [26]). Clinicopathological
features, such as histological diagnosis, estrogen receptor
(ER), progesterone receptor (PR) and human epidermal
growth factor 2 (HER2) status were retrieved from interin
pathology reports. ER, PR and HER-2 status were assessed
by immunohistochemistry. HER2 ambiguous results were
confirmed by FISH (Fluorescence in situ hybridization).
Tissue Microarray Construction
and Immunohistochemistry
Tissue microarray construction and immunohistochemistry
for hepcidin, FPN1, TfR1 and FT for this cohort have been
extensively described before [26]. Immunostaining for
hepcidin, FPN1, TfR1 and FT was evaluated in epithelial
cells, lymphocytes and macrophages using the same semi-
quantitative evaluation method as before [26]. Briefly, the
score from the percentage of positive cells (scored from 0 to
5) was multiplied by the score of the staining intensity (scored
from 0 to 3), resulting in a scale from 0 to 15. Cores from the
same donor tissue were grouped and their mean score for each
variable calculated.
DAB-Enhanced Perls’ Prussian Blue Staining
To evaluate the presence of iron deposition in breast samples,
DAB-enhanced Perls’ Prussian Blue was performed, adapted
to the Van Duijn protocol [27]. Samples’ epithelial cells and
leukocytic infiltrate were considered positive for iron deposi-
tion when at least 10% of the respective cells presented the
characteristic brown to dark staining.
DNA Extraction and HFE Genotyping
Genomic DNAwas extracted from formalin-fixed paraffin em-
bedded breast sections according to the Ultraprep Tissue DNA
kit (AHN Biotechnologie, Germany) recommended proce-
dures. PCR was carried out in 15.5 μL reaction volumes, con-
taining 2 μL of the genomic DNA template, 7.5 μL of
MasterMix DNA polymerase, 1 μL of Q-solution (Qiagen
Multiplex PCR kit, USA) and 1 μL of each of sense and anti-
sense primers. For the detection of the p.Cys282Tyr variant the
following primers were used: 5′-CAAGTGCCTCCTTT
GGTGAAGGTGACACAT-3′ as the forward primer and 5′-
CTCAGGCACTCCTCTCAACC-3′ as the reverse primer.
Following the verification of the 343 bp fragment amplifica-
tion, RsaI was used for restriction. For the HFE p.His63Asp
variant, the following forward and reverse primers’ sequences
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were used: 5′-ACATGG TTA AGG CCT GTT GC-3′ and 5′-
GCC ACA TCT GGC TTA AAA TT-3′ (primers from
Metabion, Germany). These primers amplify a fragment with
294 bp that was then restricted by MboI (enzymes from New
England Biolabs, Germany). Primers for detection of variants
in the HFE gene were chosen according to the work of Feder
et al. [28]. The PCR program included a step of 95 °C, for
15 min followed by 36 cycles of denaturation at 94 °C for
30 s, annealing at 58 °C for 90 s and extension at 72 °C for
90 s. Reaction was extended in the final for 10 min at 72 °C.
Statistical Analysis
Data was analyzed with IBM SPSS Statistics Version 18.0
(SPSS Inc., IBM, USA). Sample distributions were com-
pared by the Kruskal-Wallis test followed by post-hoc
testing whenever the omnibus testing was significant.
Pearson’s Chi-Square was used to evaluate the differences
between categorical variables. In figures, experimental er-
rors are shown as 95% Confidence Intervals (CI).
Statistical significance was accepted at p < 0.05.
Once no p.Cys282Tyr heterozygotes were found within
the aesthetic breast reduction population, comparisons for this
variant were restricted to breast cancer cases.
Results
Expression of Iron-Related Proteins
No significant differences were found in the expression of
the analyzed iron-related proteins, in all cell types,
between wild-type individuals and p.His63Asp carriers
included in the aesthetic breast reduction population.
Similarly, no significant differences were found for the
expression of these proteins in DCIS samples among all
the genotypes considered. In IDC cases, however, the ex-
pression of hepcidin in lymphocytes and macrophages was
significantly higher in patients carrying the p.Cys282Tyr
variant relative to both wild type (p = 0.049 and p = 0.050,
respectively) or p.His63Asp carriers (p = 0.016 and
p = 0.029, respectively) (Fig. 1a). No further differences
were found regarding the expression of FPN1, TfR1 and
FT in IDC cases (Fig. 1b-d).
To further clarify the relative impact of the two variants on
the results observed, we focused the analysis on a sub-sample
of p.Cys282Tyr/p.His63Asp compound heterozygotes.
Remarkably, from the 9 p.Cys282Tyr carriers with IDC, 5
also carried p.His63Asp. Although these did not differ
in general from the other p.Cys282Tyr/WT IDC pa-
tients in terms of the expression of the iron-related pro-
teins, they differed significantly from non-p.Cys282Tyr
carriers not only by a higher expression of hepcidin in
lymphocytes and macrophages (as described in the
whole p.Cys282Tyr carrier population) but they
showed, in addition, an increased expression of TfR1
in all the cell types analyzed (Table 1).
Tissue Iron Deposition
Regarding tissue iron deposition in invasive breast carcinomas,
a significantly lower percentage of p.His63Asp carrier IDC
patients presented iron deposits in epithelial (vs. p.
Cys282Tyr patients – p = 0.024; vs. WT patients – p = 0.036)
Fig. 1 Iron-related proteins in invasive breast carcinomas according to
HFE genotype. a Representative images of Hepcidin, FPN1, TfR1 and
FT immunostaining in invasive breast carcinomas. b Median hepcidin,
FPN1, TfR1 and FT expression, in epithelial cells, lymphocytes and
macrophages from invasive breast carcinomas, in relation to the
presence or absence (WT) of the p.His63Asp and p.His63Asp
variants in IDC patients. Cell types were discriminated based on their
morphology. Scores ranged from 0 to 15 and errors bars present 95%
CI. Abbreviations: WT Wild-Type, FPN1 ferroportin 1, TfR1 transferrin
receptor 1, FT ferritin, IDC Invasive Ductal Carcinoma
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and stromal inflammatory cells (vs. p.Cys282Tyr patients –
p = 0.020; vs. WT patients – p = 0.003), compared with the
two other genotypes considered (Fig. 2). Differences between
wild-type and p.Cys282Tyr heterozygotes were not statistically
significant. All p.Cys282Tyr carrier IDC patients displaying
iron deposits in epithelial cells were compound heterozygotes
and 4 out of 5 patients with iron deposition in stromal inflam-
matory cells were also compound heterozygotes.
Clinicopathological Data
Hormone receptor and HER2 status, lymph node involvement
and tumor size were available from the interin records and
were also analyzed regarding the HFE genotype. None of
the different genotypes were associated with any of the con-
sidered variables of poor outcome (Table 2).
Discussion
The knowledge of a remarkable high frequency but low pen-
etrance of the HFE variants [29] contributed to an increasing
general interest in the HFE gene as a risk factor or disease
modifier in various chronic diseases, including cancer.
However, genetic association studies have not been successful
in demonstrating a clear relationship between HFEmajor var-
iants and increased breast cancer risk [7].
In this study we approached the question of the im-
pact of HFE variants in breast cancer by looking at
their influence on the local tissue iron homeostasis.
While there is no consistent evidence that HFE variants,
in the heterozygous form, somehow influence the sys-
temic levels of hepcidin, one cannot ignore the local
iron homeostatic regulation and the possibility that an
association between HFE variants and other proteins,
such as p16, may be cell-specific or even restricted to
the neoplastic context [30].
We describe a significantly higher expression of hepcidin
in breast tissue lymphocytes and macrophages from patients
with invasive ductal carcinomas (IDC) who carry the
p.Cys282Tyr variant (Fig. 1a, Table 1) Furthermore,
p.Cys282Tyr/p.His63Asp compound heterozygous IDC pa-
tients also display enhanced expression of TfR1 in all the cell
types analyzed. The presence of the p.His63Asp and the
p.Cys282Tyr variants in compound heterozygosity has been
already associated with other conditions of altered iron han-
dling at the local level namely increased hepatic iron concen-
trations in the context of chronic liver diseases [31]. The in-
creased iron deposition in epithelial and stromal inflammatory
cells of IDC patients with the p.Cys282Tyr variant may, thus,
be a consequence of not only increased iron retention due to
the local hepcidin effect but also due to increased TfR1 ex-
pression as a result of neoplastic epithelial cells’ ‘iron-defi-
cient’ phenotype [32] and leukocyte activation [33, 34]. The
Table 1 Expression of iron-related proteins in HFE p.Cys282Tyr/p.His63Asp compound heterozygous IDC patients is increased in comparison with
patients without the p.Cys282Tyr variant
Iron-Related Proteins
(Mean ± SEM)
Non-p.Cys282Tyr
carriers (n = 47)
p.Cys282Tyr/p.His63Asp
heterozygous compounds (n = 5)
p.Cys282Tyr/WT
heterozygous (n = 4)
Hepcidin
EC 1.06 ± 0.28 3.4 ± 2.93 6.38 ± 3.33
Ly 0.80 ± 0.16 2.17 ± 0.69* 2.00 ± 0.58
M0 1.56 ± 0.32 3.60 ± 0.98* 3.83 ± 1.30
FPN1
EC 5.54 ± 0.39 6.11 ± 1.02 6.13 ± 1.71
Ly 6.67 ± 0.54 8.43 ± 1.06 4.28 ± 1.88
M0 6.17 ± 0.43 7.90 ± 0.75 4.61 ± 1.69
TfR1
EC 7.25 ± 0.51 11.00 ± 1.72* 7.65 ± 1.98
Ly 3.70 ± 0.32 5.80 ± 0.97* 4.33 ± 0.88
M0 6.14 ± 0.38 9.68 ± 1.42* 7.50 ± 2.25
FT
EC 10.09 ± 0.35 8.92 ± 0.74 9.06 ± 0.60
Ly 8.89 ± 0.24 8.50 ± 1.07 6.88 ± 0.59*
M0 14.83 ± 0.12 15.00 ± 0.00 14.17 ± 0.83
Abbreviations: IDC invasive ductal carcinoma, SEM Standard Error of the Mean, EC Epithelial Cells, Ly Lymphocytes, M0 Macrophages, NS Non-
Significant
*represents significant differences (p < 0.05) for comparison with the non-p.Cys282Tyr carriers group
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biological consequence of this altered expression of hepcidin
and TfR1, and consequently of breast tissue iron content, in
p.Cys282Tyr carriers could be a more aggressive course of
disease by favoring tumor nutrition [26]. This interpretation
may thus support other studies proposing a role forHFEmajor
variants in the regulation of breast cancer behavior [30, 35].
The fact that differences in local iron homeostasis
were found only in IDC patients may partially explain
Table 2 Clinicopathological features of breast cancer patients according to their HFE genotype
DCIS IDC
Factors WT p.Cys282Tyr p.Cys282Tyr carriers p WT p.His63Asp carriers p.Cys282Tyr carriers p
n (%) n (%) n (%) n (%) n (%) n (%)
ER status, n (%)a
negative 2 (28.6%) 1 (25.0%) 2 (66.7%) NS 7 (22.6%) 3 (16.7%) 3 (37.5%) NS
positive 5 (71.4%) 3 (75.0%) 1 (33.3%) 24 (77.4%) 15 (83.3%) 5 (62.5%)
PR status, n (%)a
negative 3 (42.9%) 2 (50.0%) 2 (66.7%) NS 8 (25.8%) 5 (27.8%) 4 (50.0%) NS
positive 4 (57.1%) 2 (50.0%) 1 (33.3%) 23 (74.2%) 13 (72.2%) 4 (50.0%)
HER2 status, n (%)a
negative 4 (57.1%) 1 (33.3%) 2 (66.7%) NS 24 (77.7%) 13 (76.5%) 4 (50.00%) NS
positive 3 (42.9%) 2 (66.7%) 1 (33.3%) 7 (22.6%) 4 (23.5%) 4 (50.00%)
LN metastasis, n (%)a
non-metastized 17 (56.7%) 4 (22.2%) 4 (50.0%) NS
metastized 13 (43.3%) 14 (77.8%) 4 (50.0%)
Median tumor size (IQR)b 1.00 (1.00–2.00) 1.00 (1.00–2.00) 1.00 (1.00–1.50) NS
Abbreviations:DCIS ductal carcinoma in situ, IDC invasive ductal carcinoma,ER estrogen receptor, PR progesterone receptor,HER2Human Epidermal
growth factor Receptor 2, LN lymph-node, IQR interquartile range, NS non-significant
a Pearson Chi-Square
b Kruskal-Wallis Test
Fig. 2 Iron deposition in invasive breast carcinomas according to the
HFE genotype. a Representative images of iron deposition in epithelial
cells and leukocyte infiltrate from invasive breast carcinomas, as detected
with DAB-enhanced Perls’ Prussian Blue staining. b Percentage of
invasive breast cancer cases presenting iron deposition, as assessed by
DAB-enhanced Perls’ Prussian Blue staining, in epithelial cells (black,
n = 51) and in the leukocyte infiltrate (grey, n = 48), in relation to theHFE
genotype. Cell types were discriminated based on their morphology.
Abbreviations: WTWild-Type
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the inconsistent results trying to relate the p.Cys282Tyr
variant and breast cancer risk, independently of the type
of tumor. While others have observed an increased prev-
alence of the p.Cys282Tyr variant with a higher num-
ber of lymph-nodes affected [36] we have not found
any association between classic clinicopathological
markers in breast cancer and any of the HFE genotypes
considered. A slightly higher prevalence of the p.
Cys282Tyr variant was observed in patients with
markers of poor outcome (ER-, PR-, HER2+) but the
insufficient sampling size does not allow us to draw
further conclusions.
In conclusion, in spite of the limitation of this study due to
low population numbers, the results give further support to the
concept of an alternative role for HFE in chronic dis-
eases through modulation of local iron homeostasis, and
highlight the need for a more insightful knowledge of
the role of HFE in cancer.
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